57332-84-0

Basic information

• Product Name: Ethyl 3-bromo-2-oxobutyrate
• Synonyms: Ethyl 3-bromo-2-oxobutyrate;3-Bromo-2-oxobutanoic acid ethyl ester;3-Bromo-2-oxo-butyric acid ethyl ester;Ethyl 3-bromo-2-oxobutanoate;Ethyl α-BroMoethylglyoxalate;3-bromo-2-keto-butyric acid ethyl ester
• CAS NO: 57332-84-0
• Molecular Formula: C₆H₉BrO₃
• Molecular Weight: 209
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 57332-84-0.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 213℃
• Flash Point: 83℃
• Appearance: /
• Density: 1.474
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform, Ethyl Acetate (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Ethyl 3-bromo-2-oxobutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-bromo-2-oxobutyrate(57332-84-0)
• EPA Substance Registry System: Ethyl 3-bromo-2-oxobutyrate(57332-84-0)

Safety Data

• Hazardous Substances Data: 57332-84-0(Hazardous Substances Data)

Usage

Chemical Properties

Ethyl 3-bromo-2-oxobutyrate is Clear Colourless Oil

Uses

Different sources of media describe the Uses of 57332-84-0 differently. You can refer to the following data:
1. Ethyl 3-bromo-2-oxobutyrate is used in the preparations of potential positron emission tomography tracers for neuropeptide Y Y1 receptors.
2. Ethyl α-Bromoethylglyoxalate is used in the preparations of potential positron emission tomography tracers for neuropeptide Y Y1 receptors.

Synthesis Reference(s)

The Journal of Organic Chemistry, 67, p. 1102, 2002 DOI: 10.1021/jo010630z

Upstream product

• 52089-54-0 ethyl 2-hydroxybutyrate 
• 56-23-5 tetrachloromethane 
• 600-18-0 2-Oxobutyric acid 
• 141-78-6 ethyl acetate 
• 15933-07-0 Ethyl 2-oxobutanoate 

Downstream Products

• 866598-56-3 ethyl 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 56355-62-5 2-bromo-5-methylthiazole-4-carboxylic acid ethyl ester 
• 796875-23-5 ethyl 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 

Relevant articles and documents

Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis

In this study, a series of 49 five-membered heterocyclic compounds containing either a pyridine- or a pyrrole-type nitrogen were synthesized and tested against Mycobacterium tuberculosis. Among them, only the 1,3,5-trisubstituted pyrazoles 5-49 exhibited

PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives

Aiming to discover melanin-concentrating hormone receptor 1 (MCHR1) antagonists with improved safety profiles, we hypothesized that the aliphatic amine employed in most antagonists reported to date could be removed if the bicyclic motif of the compound scaffold interacted with Asp123 and/or Tyr272 of MCHR1. We excluded aliphatic amines from our compound designs, with a cutoff value of pKa 8, and explored aliphatic amine-free MCHR1 antagonists in a CNS-oriented chemical space limited by four descriptors (TPSA, ClogP, MW, and HBD count). Screening of novel bicyclic motifs with high intrinsic binding affinity for MCHR1 identified the imidazo[1,2-a]pyridine ring (represented in compounds 6a and 6b), and subsequent cyclization of the central aliphatic amide linkage led to the discovery of a potent, orally bioavailable MCHR1 antagonist 4-[(4-chlorobenzyl)oxy]-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one 10a. It exhibited low potential for hERG inhibition and phospholipidosis induction as well as sufficient brain concentration to exert antiobesity effects in diet-induced obese rats.